{"id":"NCT00546052","sponsor":"Organon and Co","briefTitle":"A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)","officialTitle":"52 Week Study to Evaluate the Effects of LOSARTAN 50 mg, 100 mg, 100/12.5 mg HCTZ, 100/25 mg HCTZ on Metabolic Parameters, Blood Pressure and Safety in Hypertensive Patients With Metabolic Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09-01","primaryCompletion":"2008-01-01","completion":"2008-01-01","firstPosted":"2007-10-18","resultsPosted":"2009-06-23","lastUpdate":"2024-05-16"},"enrollment":1738,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension","Metabolic Disorder"],"interventions":[{"type":"DRUG","name":"losartan potassium (+) hydrochlorothiazide","otherNames":["Cozaar/Hyzaar"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.","primaryOutcome":{"measure":"Change in Hemoglobin A1c Between 52 Weeks and Baseline","timeFrame":"52 Weeks - Baseline","effectByArm":[{"arm":"Losartan +/- Hydrochlorothiazide","deltaMin":0.04,"sd":0.62}],"pValues":[{"comp":"OG000","p":"0.999"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20147971"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":1714},"commonTop":["Type 2 diabetes mellitus","Dizziness","Bronchitis","Osteoarthritis","Headache"]}}